340B Drug Pricing Program Press Releases

The AHA appreciates Senator Cassidy’s leadership on 340B issues. As his report correctly observes, the 340B Program was created to help hospitals reach more eligible patients and provide more comprehensive services. 

The AHA is pleased that Johnson & Johnson has decided to cease implementation of its 340B rebate proposal, which would have harmed patients and 340B providers. We are especially appreciative of HRSA’s efforts to convince J&J to put an end to this unlawful proposal and those members of Congress who demonstrated their firm support of the 340B program.

The Administration’s final rule for the 340B drug pricing program administrative dispute resolution (ADR) process is an important step in ensuring the integrity of the 340B program. The final rule contains several important process improvements, including a clear timeline for when ADR decisions must be made and an opportunity for reconsideration when parties are dissatisfied with the initial ADR decision.

Following years of litigation and a unanimous Supreme Court win, the AHA is very pleased that 340B hospitals finally will be reimbursed in full for what HHS unlawfully withheld from them for five years.

After more than five years of litigation and a unanimous Supreme Court victory, the AHA is extremely pleased that 340B hospitals will finally be paid back what they deserve so they can continue pro

The American Hospital Association (AHA), 340B Health, and the Arkansas Hospital Association told the U.S. Court of Appeals for the Eighth Circuit that Arkansas’s 340B Drug Pricing Nondiscrimination Act does not conflict with federal law but rather supports Congress’s goal in enacting the 340B program.

Hospital and pharmacist advocates for safety-net health care and affordable prescription drugs are united in their firm opposition to a misguided effort by the drug industry and some community health centers that would restrict access to the 340B drug pricing program.

The AHA will continue to fight to protect the 340B program and the patients it benefits against unfounded attacks by big drug companies.

For more than five years, the Department of Health and Human Services has unlawfully withheld vital funding from 340B hospitals that helps them provide a range of important benefits to their patients and communities. We are disappointed that the district court elected to extend this delay by remanding this case back to the department to determine the appropriate remedy.

The American Hospital Association (AHA) today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are having an adverse impact on access to care for patients and communities across the country.

While the AHA is pleased that CMS will provide hospitals and health systems with an improved update to outpatient payments next year compared to the agency’s proposal in July, the increase is still insufficient given the extraordinary cost pressures hospitals face from labor, supplies, equipment, drugs and other expenses.

The AHA appreciates Judge Contreras’ ruling that the Department of Health and Human Services must immediately stop unlawful reimbursement cuts for 2022 for hospitals participating in the 340B drug pricing program. Halting these cuts will help 340B hospitals provide comprehensive health services to their patients and communities.

Stacey Hughes Executive Vice President American Hospital Association July 15, 2022

We are pleased that the U.S. Supreme Court unanimously agreed with us that the Department of Health and Human Services' outpatient payment cuts to hospitals in the 340B Drug Pricing Program were unlawful.

We are pleased that the U.S. Supreme Court has agreed to hear the compelling arguments in our case on payments cuts to the 340B drug pricing program that are adversely impacting care to patients.

AHA statement on HRSA ordering drug companies to restore 340B discounts on drugs dispensed at community pharmacies

The leaders of six major organizations representing hospitals and pharmacists sent a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra urging him to halt the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large percentage of low-income urban and rural Americans

AHA joined by others ask U.S. Supreme Court to hear cases on 340B, hospital outpatient payment cuts

AHA urges drug companies urged to provide discounts to 340B community pharmacies.

AHA statement on HHS advisory opinion on 340B drug discounts from President and CEO Rick Pollack.